Granted Patent
B2
US 8,846,713 · App. 13/806,352 · Granted Sep 30, 2014
Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors
Inventors:
Takahiko Taniguchi (Kanagawa, JP); Masato Yoshikawa (Kanagawa, JP); Kasei Miura (Kanagawa, JP); Tomoaki Hasui (Kanagawa, JP); Eiji Honda (Kanagawa, JP); Keisuke Imamura (Kanagawa, JP); Makoto Kamata (Kanagawa, JP)
Assignee:
Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):
Claims (2)
1. 1-Ethyl-7-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, or a salt thereof.
2. A pharmaceutical composition comprising 1-ethyl-7-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, or a salt thereof, and a pharmaceutically acceptable carrier.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 6, 2026
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 075778/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 7, 2013
From: TANIGUCHI, TAKAHIKO; YOSHIKAWA, MASATO; MIURA, KASEI; HASUI, TOMOAKI; HONDA, EIJI; IMAMURA, KEISUKE; KAMATA, MAKOTO; KAMISAKI, HARUHI; QUINN, JOHN F.; RAKER, JOSEPH; CAMARA, FATOUMATA; WANG, YI
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 029939/0293 →
Continuity (3)
Provisional Application
61358121
· Jun 24, 2010
Provisional Application
61422845
· Dec 14, 2010